Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 105 от 154

Активно (без набиране) Фаза 3

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

Начало: 01.02.2024 Край: 01.06.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +10 Janssen Research & Development, LLC NCT06143878

Активно (без набиране) Фаза 1

NTI164 Human PK Study

Healthy Healthy Volunteer

This study is looking at how a new cannabis compound with extremely low THC (0.08%), NTI164, is metabolised in the body and how it is excreted in urine over time (up to 28 days) in healthy adult volunteers. NTI164 will be delivered twice daily, at a concentration of 20mg/kg/day. There will be 2 parts to this study, Part A and Part B. Part A involves only one day of taking NTI164, whereas Part B involves taking NTI164 for 7 consecutive days. Urine samples and blood samples will be collected at certain time points after NTI164 dosing to help characterise how the drug is being broken down in the body and over what time frame.

Начало: 01.02.2024 Край: 01.06.2025 Възраст: 18–65 г. Фундаментална наука

Australia Fenix Innovation Group NCT06713447

Активно (без набиране) Фаза 1/2

Study of AZD9829 in CD123+ Hematological Malignancies

Hematological Malignancies

This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematological malignancies.

Начало: 31.01.2024 Край: 23.03.2026 Възраст: от 18 г. Лечение

Australia, China, Germany +7 AstraZeneca NCT06179511

Активно (без набиране) Фаза 2

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD)

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.

Начало: 31.01.2024 Край: 30.09.2026 Възраст: от 50 г. Лечение

Australia, Japan, South Korea +1 Kyowa Kirin Co., Ltd. NCT06116890

Активно (без набиране) Фаза 3

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS)

The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).

Начало: 30.01.2024 Край: 26.12.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Bulgaria +12 Incyte Corporation NCT06212999

Активно (без набиране) Фаза 3

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Sjogren's Syndrome

Primary Objective: To evaluate the effect of dazodalibep on systemic manifestations of Sjögren's Syndrome (SS) in participants with moderate-to-severe systemic disease activity. Secondary Objectives: 1. To evaluate the effect of dazodalibep on patient reported outcomes (PROs) in participants with SS. 2. To evaluate the safety and tolerability of dazodalibep in participants with SS

Начало: 24.01.2024 Край: 19.08.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +22 Amgen NCT06104124

Активно (без набиране) Фаза 4

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cardiomyopathy, Hypertrophic

The purpose of this study is to evaluate the mavacamten impact on myocardial structure with cardiac magnetic resonance imaging (CMR) in adult participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) \[New York Heart Association (NYHA) Functional Class II or III\].

Начало: 24.01.2024 Край: 09.07.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Canada +3 Bristol-Myers Squibb NCT06112743

Активно (без набиране) Фаза 3

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

Chronic Graft Versus Host Disease

This is a parallel, Phase 3, two-arm study for the treatment of newly diagnosed moderate or severe chronic GVHD. The study duration for a participant includes up to 4 weeks for screening; a treatment period until clinically meaningful cGVHD progression (defined as progression requiring addition of new systemic treatment for cGVHD), relapse/recurrence of the underlying disease, participant starts new systemic treatment for cGVHD or experiences an unacceptable toxicity, at the request of the participants or the investigators, or until the end of study is reached, whichever comes first; at least 30 days follow-up of adverse events (AEs) after the last dose until resolution or stabilization, if applicable; and long-term follow-up until death or study close-out, whichever comes first.

Начало: 23.01.2024 Край: 29.09.2028 Възраст: от 12 г. Лечение

Argentina, Australia, Belgium +18 Sanofi NCT06143891

Активно (без набиране) Фаза 3

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

Colitis, Ulcerative

The purpose of this study is to evaluate the efficacy of guselkumab in pediatric participants with moderately to severely active ulcerative colitis at the end of maintenance therapy among participants who were induction responders.

Начало: 19.01.2024 Край: 14.08.2028 Възраст: 2–17 г. Лечение

Australia, Belgium, China +9 Janssen Research & Development, LLC NCT06260163

Активно (без набиране) Фаза 3

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Metastatic Breast Cancer

The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry \[IHC\]2+/in situ hybridization \[ISH\]- and IHC 1+) population.

Начало: 18.01.2024 Край: 01.07.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +14 DualityBio Inc. NCT06018337

Активно (без набиране) Фаза 2

Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)

Acute Kidney Injury Due to Sepsis

The purpose of this Ph2b study is to characterize the dose-response relationship and to evaluate the safety and efficacy of three different single doses of TIN816 in hospitalized adult participants in an intensive care setting with a diagnosis of sepsis-associated acute kidney injury (SA-AKI).

Начало: 18.01.2024 Край: 20.05.2026 Възраст: 18–85 г. Лечение

Argentina, Australia, Belgium +13 Novartis Pharmaceuticals NCT05996835

Активно (без набиране)

GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)

Knee Osteoarthritis

This multicenter, prospective, interventional trial is designed to assess the outcome of subjects with symptomatic knee osteoarthritis (OA) that are randomized to treatment with either genicular artery embolization (GAE) using Embosphere Microspheres or steroid injection over a period of 24 months.

Начало: 16.01.2024 Край: 01.10.2027 Възраст: от 21 г. Лечение

Australia, Brazil, Canada +3 Merit Medical Systems, Inc. NCT05818150

Активно (без набиране) Фаза 3

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

Transthyretin Amyloid Cardiomyopathy

The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause mortality (ACM) and cardiovascular (CV) clinical events.

Начало: 11.01.2024 Край: 05.10.2027 Възраст: 18–90 г. Лечение

Argentina, Australia, Belgium +21 Alexion Pharmaceuticals, Inc. NCT06183931

Активно (без набиране) Фаза 2

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

Diabetic Macular Edema (DME)

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.

Начало: 09.01.2024 Край: 30.09.2026 Възраст: от 18 г. Лечение

Australia, Japan, South Korea +1 Kyowa Kirin Co., Ltd. NCT06116916

Активно (без набиране) Фаза 2

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Advanced or Metastatic Breast Cancer

The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer. Advanced cancer is the one that is unlikely to be cured or taken care of with treatment. Metastatic cancer is the one that has spread to other parts of the body. This study is seeking female and male participants who: * are 18 years of age or older; * are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative; * have advanced or metastatic breast cancer after taking other treatments before this study; * have not taken or need to take medications that are not allowed by the study protocol; * do not have any medical or mental conditions that may increase the risk of study participation. Half of the participants will take PF-07220060 two times daily by mouth along with fulvestrant. Fulvestrant will be given as a shot into the muscle. The other half will take the study doctor's choice of treatment which can either be: * Fulvestrant alone taken as shot into the muscle. * Everolimus along with exemestane taken once daily by mouth. This study will compare the experiences of participants receiving the study medicine plus fulvestrant to those who are receiving the study doctor's choice of treatment. This will help decide if the study medicine is safe and effective. Participants will receive study treatment and/or will be in the study until: * imaging scans (such as an MRI and/or CT) show that their cancer is getting worse. * the study doctor thinks the participant is no longer benefitting from the study medicine. * has side effects that become too severe. A side effect is a reaction (expected or unexpected) to a medicine or treatment you take. * the participant chooses to stop taking part.

Начало: 09.01.2024 Край: 21.01.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +11 Pfizer NCT06105632

Активно (без набиране) Фаза 3

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

Hypophosphatasia

The primary objective of this study is to assess the efficacy of ALXN1850 versus placebo on functional outcomes in adolescent and adult participants with HPP who have not previously been treated with asfotase alfa.

Начало: 03.01.2024 Край: 29.03.2028 Възраст: 12–130 г. Лечение

Argentina, Australia, Brazil +14 Alexion Pharmaceuticals, Inc. NCT06079281

Активно (без набиране)

Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

Persistent Atrial Fibrillation

The purpose of this study is to establish the safety and effectiveness of pulsed field ablation as a first-line ablation treatment for subjects with persistent atrial fibrillation as compared to subjects who received an initial treatment with anti-arrhythmic drugs.

Начало: 28.12.2023 Край: 04.02.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +9 Boston Scientific Corporation NCT06096337

Активно (без набиране) Фаза 2

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

Non-Small Cell Lung Cancer Renal Cell Carcinoma Melanoma

The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab pembrolizumab (+) berahyaluronidase alfa \[MK-3475A\] administered subcutaneously (SC) over pembrolizumab \[MK-3475\] administered intravenously (IV) in participants with multiple tumor types. There will be no hypothesis testing in this study.

Начало: 26.12.2023 Край: 15.02.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Chile +7 Merck Sharp & Dohme LLC NCT06099782

Активно (без набиране) Фаза 3

A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndromes Leukemia, Myeloid, Acute Leukemia, Myelomonocytic, Chronic Patient Preference

It is hypothesized that significantly more patients would prefer oral decitabine/cedazuridine to subcutaneous (SC) azacitidine (AZA) due to several factors, including improved treatment convenience, the reduced risk of nosocomial infections, and reduced treatment discomfort. However, this hypothesis has not been formally studied in a controlled setting. This study aims to address this evidence gap and evaluate patient, primary caregiver (carer), and clinician treatment preference between oral decitabine/cedazuridine and SC AZA in the treatment of adult patients with International Prognostic Scoring System-Revised (IPSS-R) intermediate, IPSS intermediate-2, or high-risk myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), or low-blast (LB) acute myeloid leukemia (AML) and thereby lend further credibility to the clinical, economic, and patient value of oral decitabine/cedazuridine.

Начало: 20.12.2023 Край: 01.05.2025 Възраст: от 18 г. Лечение

Australia, New Zealand Otsuka Australia Pharmaceutical Pty Ltd NCT05883956

Активно (без набиране) Фаза 1

This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy with Envafolimab in Patients with Advanced or Metastatic Solid Tumors.

Advanced or Metastatic Solid Tumors

This is an open label, two-part, multicenter, multi-regional phase I trial to investigate the safety, tolerability, and PK of KGX101 monotherapy and combination therapy with Envafolimab in patients with advanced or metastatic solid tumors.

Начало: 13.12.2023 Край: 30.05.2026 Възраст: от 18 г. Лечение

Australia Kangabio AUSTRALIA LTD PTY NCT06074497

1 … 103 104 105 106 107 … 154